La cadena de opciones muestra datos clave de las opciones de acciones de Quantum BioPharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Quantum BioPharma..

Quantum BioPharma (NASDAQ:QNTM) Bolsa, Cadena de Opciones

Quantum BioPharma

Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEMD

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

DSGN

ELAB

KULR

LITM

MESO

NVNI

PTPI

QNTM

SGMO

SLXN

VRAX

Acciones de Sangamo Therapeutics suben un 19,5% tras un nuevo acuerdo. Descubre los mayores ganadores y perdedores de hoy.

Acciones de Sangamo Therapeutics (SGMO) suben alrededor de un 20%; 20 acciones que se mueven en el premercado

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma Ltd

Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.20) by 25 percent. This is a 21.05 percent increase over losses of $(0.19) per share from the same period last year.

Earnings

Earnings Beats

GALT

Galectin Therapeutics Q1 EPS $(0.15) Beats $(0.20) Estimate

Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) .

Guidance

Bitcoin Depot expects revenue in the Q2 2025 to grow low-to-mid-single digits on a percentage basis from the Q2 2024

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

Chemomab Therapeutics Q1 EPS $(0.007) Up From $(0.014) YoY

WIIM

Mesoblast shares are trading higher after the company secured a 7-year FDA orphan-drug exclusivity for Ryoncil in steroid-refractory pediatric graft versus host disease.

TLSA

Tiziana Life Sciences: Publishes New Study In Journal Of 'Clinical Nuclear Medicine' Demonstrating That Intranasal Administration Of Foralumab Reduces Neuroinflammation In Alzheimer's

Needham analyst Laura Martin reiterates Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Buy and maintains $18 price target.

Price Target

Reiteration

Analyst Ratings

MGNI

Needham Reiterates Buy on Magnite, Maintains $18 Price Target

<h3>Gainers</h3>
<ul>
<li>Token Cat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TC#NASDAQ">TC</a>) shares rose 13.3% to $0.85 during Thursday's pre-market session. The company's market cap stands at $2.6 million. </li>
<li>TruGolf Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) shares rose 10.16% to $0.26. The company's market cap stands at $11.4 million. </li>
<li>Ibotta (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) shares increased by 7.28% to $53.78. The market value of their outstanding shares is at $1.5 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) shares moved upwards by 7.22% to $1.78. The company's market cap stands at $85.2 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Intelligent Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTJ#NASDAQ">INTJ</a>) shares rose 6.71% to $0.64. The market value of their outstanding shares is at $8.4 million. </li>
<li>Moving iMage Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#AMEX">MITQ</a>) shares moved upwards by 6.63% to $0.62. The company's market cap stands at $6.1 million. As per the press release, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) stock fell 16.8% to $0.63 during Thursday's pre-market session. The company's market cap stands at $16.5 million. </li>
<li>Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) shares fell 14.78% to $1.9. The company's market cap stands at $246.7 million. </li>
<li>HWH International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) stock fell 12.36% to $1.56. The company's market cap stands at $10.1 million. </li>
<li>VS Media Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) stock fell 11.89% to $0.81. The company's market cap stands at $7.7 million. </li>
<li>NextPlat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>) shares declined by 9.38% to $0.58. The market value of their outstanding shares is at $15.0 million. As per the press release, Q1 earnings came out today. </li>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) shares decreased by 7.5% to $2.47. The market value of their outstanding shares is at $8.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHL

IBTA

INTJ

MITQ

NXPL

SEAT

TNMG

TRUG

UONE

VSME

12 Communication Services Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) shares increased by 85.4% to $0.84 during Thursday's pre-market session. The company's market cap stands at $20.8 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares moved upwards by 43.64% to $0.05. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) shares rose 40.74% to $1.9. The market value of their outstanding shares is at $11.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock rose 35.69% to $0.22. The company's market cap stands at $11.6 million. </li>
<li>Anbio Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNNN#NASDAQ">NNNN</a>) stock rose 22.33% to $8.6. The company's market cap stands at $377.4 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) stock increased by 20.25% to $2.85. The company's market cap stands at $250.1 million. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock fell 82.1% to $0.04 during Thursday's pre-market session. The company's market cap stands at $1.8 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock declined by 37.35% to $0.18. The market value of their outstanding shares is at $5.1 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock fell 24.51% to $0.17. The market value of their outstanding shares is at $24.1 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares declined by 20.66% to $0.12. The company's market cap stands at $10.5 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock declined by 20.16% to $3.05. The company's market cap stands at $2.5 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares decreased by 16.96% to $0.69. The company's market cap stands at $83.2 million. As per the press release, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AYTU

BDSX

EKSO

HCTI

INAB

IVVD

KLTO

NAOV

NCNA

NNNN

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Click Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) shares rose 226.7% to $0.91 during Thursday's pre-market session. The market value of their outstanding shares is at $28.9 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) stock increased by 115.56% to $0.21. The company's market cap stands at $30.6 million. </li>
<li>Innovative Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISSC#NASDAQ">ISSC</a>) stock rose 27.39% to $9.36. The market value of their outstanding shares is at $164.2 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) shares rose 16.65% to $21.99. The company's market cap stands at $1.4 billion. </li>
<li>Acuren (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TIC#AMEX">TIC</a>) stock moved upwards by 13.43% to $11.99. The company's market cap stands at $1.4 billion. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares moved upwards by 9.33% to $0.43. The market value of their outstanding shares is at $5.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Primega Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) shares fell 29.3% to $0.7 during Thursday's pre-market session. The market value of their outstanding shares is at $18.5 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) stock decreased by 19.13% to $0.32. The market value of their outstanding shares is at $39.1 million. </li>
<li>Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) stock decreased by 16.69% to $5.09. The market value of their outstanding shares is at $850.9 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares decreased by 14.02% to $0.22. The company's market cap stands at $4.6 million. </li>
<li>T1 Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TE#NYSE">TE</a>) shares declined by 13.55% to $1.34. The company's market cap stands at $188.0 million. As per the news, the Q1 earnings report came out today. </li>
<li>Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) stock fell 10.89% to $0.25. The company's market cap stands at $7.4 million. As per the press release, Q1 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLIK

HTCO

ISSC

NVEE

PGHL

SHLS

UGRO

WATT

WLGS

12 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>SmartRent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) stock moved upwards by 15.1% to $0.91 during Thursday's pre-market session. The company's market cap stands at $171.2 million. </li>
<li>Sigmatron Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) stock increased by 11.37% to $1.57. The company's market cap stands at $9.6 million. </li>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) stock increased by 10.31% to $1.14. The market value of their outstanding shares is at $8.0 million. </li>
<li>MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) shares moved upwards by 6.84% to $3.9. The company's market cap stands at $140.6 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>U-BX Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBXG#NASDAQ">UBXG</a>) shares rose 6.48% to $4.6. The company's market cap stands at $95.6 million. </li>
<li>Nvni Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) shares moved upwards by 6.08% to $0.42. The market value of their outstanding shares is at $39.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Intchains Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) shares fell 20.6% to $2.08 during Thursday's pre-market session. The company's market cap stands at $125.5 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock declined by 18.04% to $1.5. </li>
<li>DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) stock fell 13.95% to $14.25. The company's market cap stands at $2.5 billion. The company's, Q4 earnings came out yesterday. </li>
<li>Red Cat Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) stock fell 12.64% to $5.81. The company's market cap stands at $525.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Rekor Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>) stock decreased by 9.81% to $0.92. The company's market cap stands at $96.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) stock fell 9.32% to $0.55. The company's market cap stands at $10.3 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MOVE

RCAT

REKR

SGMA

SMRT

SVRE

UBXG

12 Information Technology Stocks Moving In Thursday's Pre-Market Session

Synergy CHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNYR#NASDAQ">SNYR</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.07 by 42.86 percent. The company reported quarterly sales of $8.17 million.

SNYR

Synergy CHC Q1 EPS $0.10 Beats $0.07 Estimate, Sales $8.17M Lower Than $9.41M YoY

Chardan Capital analyst Geulah Livshits maintains Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) with a Buy and lowers the price target from $13 to $12.

Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $12

Biotech

General

IMNN

IMUNON Announces Six-Month Data From Phase 1 Proof-Of-Concept Trial Of Its IMNN-101 NA Vaccine Platform; Says Its PlaCCine Platform 'demonstrates better durability and other advantages compared to mRNA vaccines'

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) announced on Wednesday that it has been chosen by <a href="https://www.benzinga.com/pressreleases/25/05/b45420724/rocket-lab-to-launch-nasa-astrophysics-science-mission-on-electron-to-study-galaxy-evolution" target="_blank" rel="noreferrer noopener">NASA </a><a href="https://www.benzinga.com/pressreleases/25/05/b45420724/rocket-lab-to-launch-nasa-astrophysics-science-mission-on-electron-to-study-galaxy-evolution" target="_blank" rel="noreferrer noopener">to launch its Aspera mission</a>.
Aspera is an astrophysics science mission designed to study the formation and evolution of galaxies and provide new insights into how the universe works.
NASA selected Rocket Lab to launch its Aspera astrophysics mission (studying galaxy formation via UV light) on Electron from Launch Complex 1, targeting no earlier than the first quarter of 2026.
Also Read: <a target="_blank" href="https://www.benzinga.com/content/45012021/rocket-lab-lands-new-contract-builds-momentum-ahead-of-earnings" rel="noreferrer noopener">Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings</a>
Aspera will utilize a telescope to observe ultraviolet light, studying the hot gas known as the intergalactic medium that exists between galaxies and is believed to play a role in the formation of stars and planets.
This mission will be the first NASA astrophysics endeavor to collect and map these ultraviolet light signatures, potentially revealing deeper insights into the origins of stars, planets, and life in the universe.
Rocket Lab founder and CEO Sir Peter Beck stated, &#8220;As a long trusted launch partner for NASA&#8217;s most pioneering small satellites, it&#8217;s great to be able to continue that support for another innovative science mission like Aspera. Electron has proven itself to be the premier small launcher through complete launch schedule control and reliably accurate orbital deployment, and we&#8217;re looking forward to delivering that again for Aspera.&#8221;
In a separate release, Rocket Lab announced that its Pioneer spacecraft&nbsp;made a successful return to Earth on Wednesday, marking the company&#8217;s second Earth return mission in two months. Varda&#8217;s W-3 mission launched <a target="_blank" href="https://www.benzinga.com/25/05/45414422/rocket-lab-stock-is-rallying-wednesday-whats-going-on" rel="noreferrer noopener">15 days after the return of W-2</a>.
Last week, the company&nbsp;reported financial results for the first quarter, with revenues of $122.57 million, beating the&nbsp;consensus&nbsp;estimate of $121.38 million and loss of 12 cents per share, beating analyst estimates <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45327779/rocket-labs-new-defense-deal-2025-forecast-win-analyst-support" rel="noreferrer noopener">of 13 cents loss per share</a>.
Investors can gain exposure to the stock via&nbsp;ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) and Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>).
Price Action: RKLB shares are down 2.40% at $23.55 premarket at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45143330" target="_blank" rel="noreferrer noopener">AI, Hypersonics,&nbsp;$24 Billion&nbsp;Market: Portfolio Manager Gives A Peek Inside GCAD&#8217;s Bet On Drone Warfare Dominance</a></li>
</ul>
Image by Emagnetic via Shutterstock

Equities

Large Cap

Contracts

ARKX

RKLB

Rocket Lab Gets NASA Contract To Launch Aspera Astrophysics Mission

<ul>
<li>Blue Owl Digital Infrastructure Fund III seeks to support the global capital demands of&nbsp;hyperscalers, fueled by ongoing investments in data centers and artificial intelligence.</li>
</ul>
NEW YORK, May 15, 2025 /PRNewswire/ -- Blue Owl Capital Inc. ("Blue Owl") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>), a leading alternative asset manager, announced today the final close of its most recent digital infrastructure fund, Blue Owl Digital Infrastructure Fund III ("ODI III") with $7 billion of total capital commitments. ODI III exceeded the original target of $4 billion and hit its hard cap.
ODI III will focus on developing, acquiring, and owning data centers and other connectivity related real assets to help meet the AI and cloud-driven global digital capacity needs of the world's largest technology companies, with a focus on large-scale, build-to-suit developments.

Blue Owl Closes $7B Digital Infrastructure Fund III To Support Hyperscaler Demand Amid AI And Cloud Boom, Surpassing $4B Target To Invest In Data Centers And Connectivity Assets Worldwide

<a href="https://www.globenewswire.com/Tracker?data=1Cv5vc6xPugdycgEI5g5MdjtOphqPViQBh2de9Wew2xQaCN7hVFga3quhCMOlC-V5wWvMzxJvQZavTaoOXF6bg==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) ("Merus", "the Company", "we", or "our"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics&#xAE;, Triclonics&#xAE; and ADClonics&#xAE;), today announced publication on the mechanism of action of petosemtamab, a bispecific antibody targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G (LGR5), in the scientific journal "Cancers", a MDPI publication, available <a href="https://www.globenewswire.com/Tracker?data=qDy227Jlbf1q1FH5Gxy-pD1yN8G32hMajPBa7ZAAO61n2po-XuClGyspYfkeqMv_Yt_DqAC3_Jcym2YqyszV_3-VsruA190TW6MqqQ6agkc=">here</a>.

MRUS

Merus Announces Publication On Mechanism Of Action Of Petosemtamab, Bispecific Antibody Targeting EGFR And LGR5, In Scientific Journal "Cancers"

Youdao shares are trading higher after the company reported a year-over-year increase in Q1 EPS results.

HC Wainwright &amp; Co. analyst Sean Lee reiterates CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Neutral and maintains $1 price target.

CTSO

HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target

Acuren shares are trading higher after the company announced a merger with NV. Also, the company announced it has been approved for uplisting to the NYSE.

IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) reported quarterly earnings of $0.06 per share. This is a 103.23 percent increase over losses of $(1.86) per share from the same period last year. The company reported $8.71 million in sales this quarter. This is a 2.69 percent decrease over sales of $8.95 million the same period last year.

IMCC

IM Cannabis Q1 EPS $0.06 Up From $(1.86) YoY, Sales $8.71M Down From $8.95M YoY

Press Releases

Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern

Financing

Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms

Health Care

Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis

Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico

Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™

Legal

Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario

Management

Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor

Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time

Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis

CSE:HUGE

CSE:QNTM

HUGE

Comments

Quantum BioPharma

Quantum BioPharma (QNTM) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL